Navigation Links
HeartWare Presentation at the UBS Global Life Sciences Conference to be Webcast
Date:9/14/2012

FRAMINGHAM, Mass. and SYDNEY, Sept. 14, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the UBS Global Life Sciences Conference at 8:00 a.m. EDT on Wednesday, September 19, 2012.  The conference is being held September 19-20, 2012 at the Grand Hyatt in New York City.

A live webcast of the Company's presentation at the conference will be available via a link provided at www.heartware.com.  A replay of the webcast will be available for 90 days at the site after the presentation.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  HeartWare has received CE Marking for the HeartWare System in the European Union and TGA approval in Australia.  The device is currently the subject of United States clinical trials for two indications: bridge-to-transplant and destination therapy.  For additional information, please visit www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

HEARTWARE, HVAD, MVAD a
'/>"/>

SOURCE HeartWare International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. HeartWare Presentation At The Canaccord Genuity 32nd Annual Growth Conference To Be Webcast
2. HeartWare Presentation at the 2012 Wedbush PacGrow Lifesciences Management Access Conference to be Webcast
3. HeartWare Reports Second Quarter 2012 Results
4. HeartWare Completes Acquisition Of World Heart Corporation
5. HeartWare Schedules Second Quarter Conference Call And Webcast
6. HeartWare Names Peter F. McAree Chief Financial Officer
7. HeartWare International Receives CE Mark Addendum, Expanding Label to Include All Patients at Risk of Death From Refractory, End-Stage Heart Failure
8. HeartWare Completes Enrollment In 450-Patient Pivotal Destination Therapy Clinical Trial
9. HeartWare Presentation at the Bank of America Merrill Lynch 2012 Health Care Conference to be Webcast
10. Heartware Schedules First Quarter Conference Call And Webcast
11. HeartWare Stock Trading Halted Today; FDA Advisory Committee to Review HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... -- Strategic Health Services, Inc. (SHS), a leading provider of ... agreement with QualCare, Inc., a leading provider of health plans ... marketplace.  This agreement will further QualCare,s population health management ... brings to its clients in New Jersey ... QualCare plans cover more than 800,000 member lives, with ...
(Date:12/17/2014)... December 17, 2014 , ... than a hub of information concerning the biopharmaceutical Group,s national ... A further addition to the recently launched institutional website that ... now been enriched by a new chapter in the fascinating ... A richly detailed and panoramic hub on the world of ...
(Date:12/17/2014)... Ga. and RALEIGH, N.C. ... Trial Marketing Communications, LLC (CTMC), and Integrated Clinical ... patient recruitment and retention for clinical trials announce ... Integrated Clinical Trial Marketing Services (i-CTMS). i-CTMS will ... retention services to pharmaceutical, biotechnology and medical device ...
Breaking Medicine Technology:Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 2Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 3Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3
... France and SWIFTWATER, Pa., June 16 Sanofi,Pasteur, the ... donate 60 million doses of H5N1 vaccine to the ... of an H5N1 vaccine,global stockpile., "The H5N1 virus ... the world and an outbreak of pandemic influenza would ...
... Results presented at the 90th annual Endocrine Society meeting show,significant ... ... painful intercourse, ANN ARBOR, Mich, June 16 QuatRx ... 3 clinical,trial of Ophena(TM) (ospemifene tablets) to treat postmenopausal women ...
Cached Medicine Technology:Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile 2Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile 3Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile 4Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile 5Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy 2Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy 3Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy 4
(Date:12/19/2014)... 19, 2014 Eufaula, Oklahoma, located just ... Eufaula, the state’s largest lake with more than 600 ... home to a little more than 3,000 residents, hosted ... Saturday, the 6th of December. , Featuring Santa, Christmas ... downtown Eufaula on Main Street. Narconon Arrowhead’s parade ...
(Date:12/19/2014)... The print component of Vision and ... of the Toronto Star, with a circulation of approximately ... digital component is distributed nationally through a vast social ... sites and partner outlets. To explore the digital version ... publication features an exclusive interview with Mark DeMontis ...
(Date:12/19/2014)... 19, 2014 (HealthDay News) -- Potentially illness-causing E. coli ... at farmers markets, according to a new study. ... vendors from 13 farmers markets in Los Angeles and ... Out of almost 150 samples tested, 24 percent were ... salmonella, according to the researchers. Both types of ...
(Date:12/19/2014)... who have lost all their teeth have faster decreases in ... least some of their teeth, a new study says. ... early warning of increased risk of physical and mental decline ... findings don,t prove that tooth loss causes the physical or ... 60 and older. People with no remaining teeth did about ...
(Date:12/19/2014)... Kan. (PRWEB) December 19, 2014 B. ... exclusively to healthcare providers, has been retained to lead ... Estes Park Medical Center in Estes Park, Colo. The ... E. Smith has recently placed more than 900 healthcare ... (EPMC) is a 25-bed, not-for-profit critical access hospital and ...
Breaking Medicine News(10 mins):Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 3Health News:Mark DeMontis, Founder of Courage Canada, shares his passion for bringing hockey to those affected by blindness in Mediaplanet’s “Vision and Hearing” campaign 2Health News:E. Coli Germs Found on Farmers Market Herbs 2Health News:Loss of Teeth Linked to Physical, Mental Decline in Study 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 3
... SHANGHAI, China, Feb. 11 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc.,(Nasdaq: ... leading Chinese firm,specializing in the research, development, manufacture, ... it will host a,conference call at 10:00 a.m. ... Company,s financial results for the third quarter ended ...
... privately held company located in the Midwest, has just ... of the most common problems associated with wearing a ... always been therapeutic for many people. The Annals of ... therapy beyond the first night ... because they find ...
... of tracking changes proves better predictor than PSA, study ... for changes in the number of circulating tumor cells ... survival and response to treatment, U.S. researchers report. , ... after treatment) and survival, along with other factors such ...
... 11 Tibotec Therapeutics, a division of Centocor ... of a lower-dose (75 mg) formulation of PREZISTA ... follows the FDA approval of PREZISTA, co-administered with ... the treatment of HIV infection in pediatric patients ...
... 11 Solos Endoscopy, Inc. (Pink Sheets: SNDY) is ... financials through the first nine months of 2008 on ... generated through the nine-months of 2008 amounted to $304,559, ... The Company substantially lowered its General and Administrative expense ...
... Men, Women Differ in Oral Health Care Habits , CHICAGO, ... what do people find most attractive in others? The smile. ... Crest(R) and Oral B(R) finds that the smile outranked eyes, ... men and women differ when it comes to taking care ...
Cached Medicine News:Health News:China-Biotics, Inc. Announces Conference Call to Discuss Third Quarter 2009 Financial Results 2Health News:China-Biotics, Inc. Announces Conference Call to Discuss Third Quarter 2009 Financial Results 3Health News:Husband From Small Town May Have Found Solution to Sleep Industry's 20-Year Compliance Problem 2Health News:Levels of Circulating Tumor Cells Could Predict Prostate Cancer Outcome 2Health News:PREZISTA(R) Now Available for Pediatric Patients Six Years of Age and Older as part of HIV Combination Therapy 2Health News:PREZISTA(R) Now Available for Pediatric Patients Six Years of Age and Older as part of HIV Combination Therapy 3Health News:PREZISTA(R) Now Available for Pediatric Patients Six Years of Age and Older as part of HIV Combination Therapy 4Health News:PREZISTA(R) Now Available for Pediatric Patients Six Years of Age and Older as part of HIV Combination Therapy 5Health News:PREZISTA(R) Now Available for Pediatric Patients Six Years of Age and Older as part of HIV Combination Therapy 6Health News:PREZISTA(R) Now Available for Pediatric Patients Six Years of Age and Older as part of HIV Combination Therapy 7Health News:Solos Endoscopy, Inc. Posts First Nine Months Financials for 2008 on Pinksheets.com 2Health News:Survey Finds Smile is 'Most Attractive' Physical Feature 2
The Fujinon's R410 laparoscope is the first to bring a 410,000 pixel CCD to the end of the scope. Superior imaging and color replication, along with a unique lens washing capability make the R410 the...
The ACMI™ Operative Laparoscopy System is designed for single- and dual-incision CO2 laser procedures and is used with 45cm laparoscopic instruments....
The edge-to-edge clarity of the laparoscopes provides excellent image definition.Even small structures are easily recognized due to the optimal depth of focus. The outstanding optical quality provide...
Stryker bariatric laparoscopes set the standard in picture quality....
Medicine Products: